Editorial Standards

Editorial Principles

Every page on stemcyte.com is developed against five non-negotiable principles:

• Accuracy. Every clinical or scientific claim is supported by a primary source, a regulatory filing, or guidance from a recognized medical body.
• Clarity. Medical information is written so that a non-clinical reader can understand it, without sacrificing precision.
• Transparency. We name our sources, link to them where possible, and distinguish between established treatments, active research, and theoretical applications.
• Accountability. Our Chief Medical Officer is the named medical authority for content published under the StemCyte name.
• Currency. Content is reviewed on a defined cadence and updated when the underlying science or regulation changes.

Content Categories and Review Tiers

Not all content carries equal medical weight. We apply different levels of review based on the nature of the information:

• Clinical content. Pages describing active clinical trials, the Expanded Access Program, and FDA-licensed products. Reviewed by the Chief Medical Officer and, where applicable, by the regulatory affairs team. Reviewed quarterly or sooner if regulatory status changes.
• Educational content. Pages explaining cord blood, cord tissue, stem cells, HLA matching, and related medical concepts. Reviewed by the Chief Medical Officer. Reviewed annually or sooner when new clinical evidence emerges.
• Service content. Pages describing our banking plans, processing methods, storage, and operational programs. Reviewed by marketing and operations for accuracy. Medical claims within these pages are subject to medical review.
• Corporate content. Pages covering company history, leadership, careers, and press. Reviewed by internal communications. Factual claims about clinical track record or accreditation are verified against source documents before publication.

Medical Review

Medical content on stemcyte.com is reviewed by Joseph Rosenthal, MD, our Chief Medical Officer.

Dr. Rosenthal is Professor Emeritus at City of Hope, where he served for more than 25 years, including more than a decade as the Barron Hilton Chair in Pediatrics and Director of Pediatric Hematology-Oncology. He is a recognized expert in bone marrow transplantation and umbilical cord blood therapy and has published widely in the field.

Dr. Rosenthal reviews and approves the substantive medical content on our website. For pages tied to active clinical programs or FDA-regulated products, this review is conducted in coordination with our regulatory affairs function. Where Dr. Rosenthal has reviewed a page, this is indicated on the page itself.

Dr. Rosenthal's role is described in detail on his leadership profile. View profile.

Sourcing and Citation Standards

We rely on primary sources first. In order of preference:

• Peer-reviewed publications indexed in PubMed, the Cochrane Library, or equivalent scientific databases.
• Regulatory documents issued by the U.S. Food and Drug Administration, including approval letters, package inserts, and guidance documents.
• Clinical practice guidelines from recognized medical bodies, including the American College of Obstetricians and Gynecologists (ACOG), the American Society for Transplantation and Cellular Therapy (ASTCT), and the FACT-NetCord International Standards.
• Registered clinical trial records on ClinicalTrials.gov.
• Accreditation records from AABB and FACT.

Sources cited across the site are consolidated and made browsable at our citations page. Where a claim on the site cannot be supported by one of the source categories above, we either qualify the claim ("according to the company," "early-phase research," "being studied") or remove it.

Accuracy and Corrections

If we publish information that is incorrect, we correct it. Our practice is:

• Substantive medical or factual errors are corrected as soon as practical, typically within five business days of verification.
• Where a correction materially changes the meaning of a statement, the prior text is replaced and the page's reviewed date is updated.
• We do not silently revise historical numbers (such as transplant counts or trial outcomes). When such figures are updated, the new figure replaces the prior one, and the change is reflected in our newsroom or in the source citation.

If you believe a page on this site contains an inaccuracy, please contact us using the address in Section 8.

Regulatory and Promotional Compliance

StemCyte holds FDA US License 2280 for REGENECYTE® (HPC, Cord Blood), our FDA-licensed cord blood product. Content that describes REGENECYTE® or any other FDA-regulated product is subject to additional review:

• Promotional content involving REGENECYTE® is reviewed against the requirements of 21 CFR 202.1 (Prescription drug advertising) and applicable FDA guidance on prescription drug promotion.
• We do not promote investigational uses of any product. References to clinical trials, RMAT designation, or Expanded Access programs describe the regulatory status of the program, not the safety or efficacy of an unapproved use.
• Off-label discussion of any FDA-regulated product is prohibited in promotional contexts on this site.

Content describing our banking services, processing methods, and educational material is governed by general FTC truth-in-advertising standards and applicable state law. We do not make medical efficacy claims outside the scope of established treatments.

Contact

Editorial questions, source verification requests, and correction notices can be sent to: